MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

NCT07502222 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2026-03-30

No results posted yet for this study

Summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.

Conditions

Interventions

BIOLOGICAL

AK139 and placebo

AK139 plus placebo regimen 1-subcutaneous injection.

BIOLOGICAL

AK139

AK139 regimen 2-subcutaneous injection.

BIOLOGICAL

AK139 and placebo

AK139 plus placebo regimen 3-subcutaneous injection.

BIOLOGICAL

AK139

AK139 regimen 4-subcutaneous injection.

BIOLOGICAL

AK139 and placebo

AK139 plus placebo regimen 5-subcutaneous injection.

BIOLOGICAL

AK139 and placebo

AK139 plus placebo regimen 6-subcutaneous injection.

BIOLOGICAL

Placebo

Placebo-subcutaneous injection

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-07
Primary Completion
2027-11-30
Completion
2028-01-10

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07502222 on ClinicalTrials.gov